A story in the June 14, 2005, issue of BioWorld Today should have said Metabasis Therapeutics Inc. and Sankyo Co. Ltd.'s drug candidate CS-917 alone was not directly responsible for two serious adverse events of lactic acidosis. Patients with SAEs already had elevated levels of metformin when they entered trials, and those levels rose higher when given CS-917 with metformin, so the two will not be tested together until the specific cause is understood.

Editor's note: The change has been made in BioWorld Online.